Accepted Manuscript

Is atherosclerosis imaging the most sensitive way to assess patients' risk and the best way to conduct future drug trials? A pros-and-cons debate

David Nanchen, Paolo Raggi

PII: S0021-9150(17)31246-7

DOI: 10.1016/j.atherosclerosis.2017.08.024

Reference: ATH 15179

To appear in: Atherosclerosis

Received Date: 5 July 2017

Revised Date: 7 August 2017 Accepted Date: 23 August 2017

Please cite this article as: Nanchen D, Raggi P, Is atherosclerosis imaging the most sensitive way to assess patients' risk and the best way to conduct future drug trials? A pros-and-cons debate, *Atherosclerosis* (2017), doi: 10.1016/j.atherosclerosis.2017.08.024.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

Is atherosclerosis imaging the most sensitive way to assess patients' risk and the best way to conduct future drug trials? A pros-and-cons debate

¹ David Nanchen, ²Paolo Raggi

Correspondence: Mazankowski Alberta Heart Institute, University of Alberta

4A7.050, 8440 - 112 Street, Edmonton, AB T6G 2B7, Canada

Email address: raggi@ualberta.ca (P. Raggi)

¹ Department of Ambulatory Care and Community Medicine, University of Lausanne, Lausanne, Switzerland

² Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, AB, Canada

Download English Version:

https://daneshyari.com/en/article/8657095

Download Persian Version:

https://daneshyari.com/article/8657095

<u>Daneshyari.com</u>